Dianthus Therapeutics, Inc. /DE/ Operating Expenses
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Operating Expenses of $62.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ operating expenses for the quarter ending 2026-06-30 was $62.24M, a 77.23% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ operating expenses for the quarter ending 2026-03-31 was $47.00M, a 36.85% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ operating expenses for the quarter ending 2025-12-31 was $69.83M, a 110.05% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ operating expenses for the quarter ending 2025-09-30 was $40.68M, a 26.85% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ operating expenses for fiscal 2025 was $179.97M, a 66.49% increase from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ operating expenses for fiscal 2024 was $108.10M, a 111.96% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ operating expenses for fiscal 2023 was $51.00M, a 41.19% increase from fiscal 2022.
- Dianthus Therapeutics, Inc. /DE/ operating expenses for fiscal 2022 was $36.12M.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $62.24M 10-Q · filed 2026-08-04 | $109.24M 10-Q · filed 2026-08-04 | $179.06M derived: sum of 3 quarters · filed 2026-08-04 | $219.75M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $47.00M 10-Q · filed 2026-05-05 | $116.82M derived: sum of 2 quarters · filed 2026-05-05 | $157.50M derived: sum of 3 quarters · filed 2026-05-05 | $192.63M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $69.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $110.51M derived: sum of 2 quarters · filed 2026-03-09 | $145.63M derived: sum of 3 quarters · filed 2026-08-04 | $179.97M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $40.68M 10-Q · filed 2025-11-05 | $75.80M derived: sum of 2 quarters · filed 2026-08-04 | $110.14M 10-Q · filed 2025-11-05 | $143.39M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $35.12M 10-Q · filed 2026-08-04 | $69.46M 10-Q · filed 2026-08-04 | $102.70M derived: sum of 3 quarters · filed 2026-08-04 | $134.77M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $34.34M 10-Q · filed 2026-05-05 | $67.58M derived: sum of 2 quarters · filed 2026-05-05 | $99.65M derived: sum of 3 quarters · filed 2026-05-05 | $123.72M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $33.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $65.31M derived: sum of 2 quarters · filed 2026-03-09 | $89.38M derived: sum of 3 quarters · filed 2026-03-09 | $108.10M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $32.07M 10-Q · filed 2025-11-05 | $56.14M derived: sum of 2 quarters · filed 2025-11-05 | $74.86M 10-Q · filed 2025-11-05 | $88.27M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $24.07M 10-Q · filed 2025-08-07 | $42.78M 10-Q · filed 2025-08-07 | $56.20M derived: sum of 3 quarters · filed 2025-08-07 | $72.88M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $18.72M 10-Q · filed 2025-05-12 | $32.13M derived: sum of 2 quarters · filed 2025-05-12 | $48.81M derived: sum of 3 quarters · filed 2025-05-12 | $61.56M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $13.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $30.10M derived: sum of 2 quarters · filed 2025-03-11 | $42.84M derived: sum of 3 quarters · filed 2025-03-11 | $51.00M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $16.68M 10-Q · filed 2024-11-07 | $29.43M derived: sum of 2 quarters · filed 2024-11-07 | $37.59M 10-Q · filed 2024-11-07 | $49.45M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $12.74M 10-Q · filed 2024-08-08 | $7.38M 10-Q · filed 2023-08-03 | $20.90M 10-Q · filed 2024-08-08 | $39.51M 10-Q · filed 2023-08-03 | $32.77M derived: sum of 3 quarters · filed 2024-08-08 | $42.20M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $8.16M 10-Q · filed 2024-05-09 | $32.13M 10-Q · filed 2023-05-15 | $20.03M derived: sum of 2 quarters · filed 2024-05-09 | $29.45M derived: sum of 3 quarters · filed 2024-05-09 | $47.54M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $11.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $21.30M derived: sum of 2 quarters · filed 2024-03-21 | $39.38M derived: sum of 3 quarters · filed 2024-03-21 | $36.12M 10-K · filed 2024-03-21 | $80.90M 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $9.43M 10-Q · filed 2023-11-09 | $17.25M 10-Q · filed 2022-11-03 | $27.51M derived: sum of 2 quarters · filed 2023-11-09 | $24.25M 10-Q · filed 2023-11-09 | $59.17M 10-Q · filed 2022-11-03 | $11.35M derived: sum of 4 quarters · filed 2023-12-21 | ||
| 2022-06-30 | $18.08M 10-Q · filed 2023-08-03 | $41.92M 10-Q · filed 2023-08-03 | $1.93M derived: sum of 3 quarters · filed 2023-12-21 | $20.17M derived: sum of 4 quarters · filed 2023-12-21 | ||||
| 2022-03-31 | $23.83M 10-Q · filed 2023-05-15 | -$16.16M derived: sum of 2 quarters · filed 2023-12-21 | $2.09M derived: sum of 3 quarters · filed 2023-12-21 | $19.70M derived: sum of 4 quarters · filed 2023-12-21 | ||||
| 2021-12-31 | -$39.99M derived: 8-K 12 month − 10-Q 9 month · filed 2023-12-21 | -$21.75M derived: sum of 2 quarters · filed 2023-12-21 | -$4.13M derived: sum of 3 quarters · filed 2023-12-21 | $14.56M 8-K · filed 2023-12-21 | $74.69M 10-K · filed 2022-03-08 | |||
| 2021-09-30 | $18.25M 10-Q · filed 2022-11-03 | $35.85M derived: sum of 2 quarters · filed 2022-11-03 | $54.55M 10-Q · filed 2022-11-03 | $73.62M derived: sum of 4 quarters · filed 2022-11-03 | ||||
| 2021-06-30 | $17.61M 10-Q · filed 2022-08-04 | $36.31M 10-Q · filed 2022-08-04 | $55.37M derived: sum of 3 quarters · filed 2022-08-04 | $73.75M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $18.70M 10-Q · filed 2022-05-16 | $37.76M derived: sum of 2 quarters · filed 2022-05-16 | $56.14M derived: sum of 3 quarters · filed 2022-05-16 | $76.16M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $19.07M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $37.45M derived: sum of 2 quarters · filed 2022-03-08 | $57.46M derived: sum of 3 quarters · filed 2022-03-08 | $78.70M 10-K · filed 2022-03-08 | ||||
| 2020-09-30 | $18.38M 10-Q · filed 2021-11-04 | $38.39M derived: sum of 2 quarters · filed 2021-11-04 | $59.64M 10-Q · filed 2021-11-04 | $84.27M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-06-30 | $20.01M 10-Q · filed 2021-08-05 | $41.26M 10-Q · filed 2021-08-05 | $65.89M derived: sum of 3 quarters · filed 2021-08-05 | $88.54M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | $21.24M 10-Q · filed 2021-05-06 | $45.88M derived: sum of 2 quarters · filed 2021-05-06 | $68.53M derived: sum of 3 quarters · filed 2021-05-06 | $87.86M derived: sum of 4 quarters · filed 2021-05-06 | ||||
| 2019-12-31 | $24.64M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $47.28M derived: sum of 2 quarters · filed 2021-03-03 | $66.62M derived: sum of 3 quarters · filed 2021-03-03 | $82.97M 10-K · filed 2021-03-03 | ||||
| 2019-09-30 | $22.64M 10-Q · filed 2020-11-05 | $41.98M derived: sum of 2 quarters · filed 2020-11-05 | $58.33M 10-Q · filed 2020-11-05 | $76.26M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $19.34M 10-Q · filed 2020-08-06 | $35.69M 10-Q · filed 2020-08-06 | $53.62M derived: sum of 3 quarters · filed 2020-08-06 | $70.32M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | $16.35M 10-Q · filed 2020-05-07 | $34.28M derived: sum of 2 quarters · filed 2020-05-07 | $50.98M derived: sum of 3 quarters · filed 2020-05-07 | $65.01M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $17.93M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $34.63M derived: sum of 2 quarters · filed 2020-03-03 | $48.66M derived: sum of 3 quarters · filed 2020-03-03 | $59.96M 10-K · filed 2020-03-03 | ||||
| 2018-09-30 | $16.70M 10-Q · filed 2019-11-13 | $30.73M derived: sum of 2 quarters · filed 2019-11-13 | $42.03M 10-Q · filed 2019-11-13 | $50.20M derived: sum of 4 quarters · filed 2020-03-03 | ||||
| 2018-06-30 | $14.03M 10-Q · filed 2019-08-08 | $25.33M 10-Q · filed 2019-08-08 | $33.50M derived: sum of 3 quarters · filed 2020-03-03 | $40.52M derived: sum of 4 quarters · filed 2020-03-03 | ||||
| 2018-03-31 | $11.31M 10-Q · filed 2019-05-09 | $19.48M derived: sum of 2 quarters · filed 2020-03-03 | $26.49M derived: sum of 3 quarters · filed 2020-03-03 | $42.22M derived: sum of 4 quarters · filed 2020-03-03 | ||||
| 2017-12-31 | $8.17M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03 | $15.19M derived: sum of 2 quarters · filed 2020-03-03 | $30.92M derived: sum of 3 quarters · filed 2020-03-03 | $35.73M 10-K · filed 2020-03-03 | ||||
| 2017-09-30 | $7.01M 10-Q · filed 2018-11-08 | $22.75M derived: sum of 2 quarters · filed 2018-11-08 | $27.56M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | $15.73M 10-Q · filed 2018-08-09 | $20.54M 10-Q · filed 2018-08-09 | ||||||
| 2016-12-31 | $9.27M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |